» Articles » PMID: 7416742

Incidence of Polyene-resistant Yeasts Recovered from Clinical Specimens

Overview
Specialty Pharmacology
Date 1980 Jul 1
PMID 7416742
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

The development of resistance to amphotericin B and nystatin in yeast isolates was determined. Organisms recovered from patients on the oncology service, undergoing extensive chemotherapy for acute leukemia and bone marrow transplantation, were compared with yeasts recovered from patients on other services in the same hospital over a 7-month period. An agar dilution method was used to assay the susceptibility for each antibiotic; resistance was defined as a minimal inhibitory concentration of greater than or equal to 2 micrograms/ml for amphotericin B and greater than or equal to 16 micrograms/ml for nystatin. None of 625 isolates from 238 patients on non-oncology services demonstrated polyene resistance. Resistance only occurred in a subpopulation of oncology patients, in which 55 isolates (7.4%) from six patients (8.6%) exhibited polyene resistance. Resistance yeasts included Candida albicans (three strains), Candida tropicalis (one strain), and Torulopsis glabrata (two strains). All of the patients from whom resistant yeasts were recovered had experienced extensive chemotherapy with cytotoxic agents, granulocytopenia, and long-term treatment with both antibacterial and polyene antibiotics. Resistance to 2 micrograms of amphotericin B per ml and to 16 micrograms of nystatin per ml was associated with loss or marked depression of ergosterol in the cell membrane as measured by ultraviolet spectra. A significant incidence of polyene resistance in an oncology subpopulation was documented, suggesting a need for susceptibility testing in patients who are at high risk for development of drug-resistant fungal pathogens.

Citing Articles

The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.

Zobi C, Algul O Chem Biol Drug Des. 2025; 105(1):e70045.

PMID: 39841631 PMC: 11753615. DOI: 10.1111/cbdd.70045.


Recent Perspectives in the Management of Fungal Keratitis.

Raj N, Vanathi M, Ahmed N, Gupta N, Lomi N, Tandon R J Fungi (Basel). 2021; 7(11).

PMID: 34829196 PMC: 8621027. DOI: 10.3390/jof7110907.


Molecular Markers of Antifungal Resistance: Potential Uses in Routine Practice and Future Perspectives.

Garcia-Effron G J Fungi (Basel). 2021; 7(3).

PMID: 33803304 PMC: 7998127. DOI: 10.3390/jof7030197.


Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.

Cavassin F, Bau-Carneiro J, Vilas-Boas R, Queiroz-Telles F Infect Dis Ther. 2021; 10(1):115-147.

PMID: 33523419 PMC: 7954977. DOI: 10.1007/s40121-020-00382-7.


Antimicrobial Metal Nanomaterials: From Passive to Stimuli-Activated Applications.

Cheeseman S, Christofferson A, Kariuki R, Cozzolino D, Daeneke T, Crawford R Adv Sci (Weinh). 2020; 7(10):1902913.

PMID: 32440470 PMC: 7237851. DOI: 10.1002/advs.201902913.


References
1.
Woods R, Bard M, Jackson I, Drutz D . Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J Infect Dis. 1974; 129(1):53-8. DOI: 10.1093/infdis/129.1.53. View

2.
Pappagianis D, Collins M, Hector R, Remington J . Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979; 16(2):123-6. PMC: 352808. DOI: 10.1128/AAC.16.2.123. View

3.
BODENHOFF J . Development of strains of genus Candida and genus Torulopsis resistant to antimycotics. Acta Pathol Microbiol Scand. 1969; 75(4):622-30. View

4.
Drutz D, Lehrer R . Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci. 1978; 276(1):77-92. View

5.
Thompson E, STARR P, Parks L . Sterol accumulation in a mutant of Saccharomyces cerevisiae defective in ergosterol production. Biochem Biophys Res Commun. 1971; 43(6):1304-9. DOI: 10.1016/s0006-291x(71)80014-1. View